{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:56:49Z","timestamp":1768525009339,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.autrev.2023.103286","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:30:07Z","timestamp":1675348207000},"page":"103286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["COVID-19 and autoimmune bullous diseases: Lessons learned"],"prefix":"10.1016","volume":"22","author":[{"given":"Michael","family":"Kasperkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Woodley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103286_bb0005","series-title":"StatPearls [Internet]","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022"},{"key":"10.1016\/j.autrev.2023.103286_bb0010","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103286_bb0015","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0020","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103286_bb0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103286_bb0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"French study group on auto immune bullous skin diseases, and the French network of rare diseases in dermatology (FIMARAD). Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: a nationwide study","volume":"86","author":"Joly","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2021.02.087","article-title":"The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: a population-based cohort study","volume":"85","author":"Kridin","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0045","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jaad.2020.12.043","article-title":"Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study","volume":"84","author":"Mahmoudi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15417","article-title":"COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients","volume":"35","author":"\u00d6zgen","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103286_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15672","article-title":"Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: a historical cohort study","volume":"35","author":"Moghadam","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103286_bb0060","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/jdv.18538","article-title":"Rituximab in immunobullous disorders during the COVID-19 pandemic: a systematic review of observational studies","volume":"37","author":"Kasperkiewicz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdin.2022.01.003","article-title":"SARS-CoV-2 infections in patients with autoimmune blistering disorders: a case series and retrospective analysis","volume":"7","author":"Breglio","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.autrev.2023.103286_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14647","article-title":"Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?","volume":"34","author":"Uzuncakmak","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103286_bb0075","doi-asserted-by":"crossref","first-page":"1080786","DOI":"10.3389\/fimmu.2022.1080786","article-title":"Targeting heat shock proteins 90 and 70: a promising remedy for both autoimmune bullous diseases and COVID-19","volume":"13","author":"Kasperkiewicz","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103286_bb0080","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1111\/jdv.17228","article-title":"COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the international pemphigus and pemphigoid foundation","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13695","article-title":"Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy","volume":"33","author":"Brunasso","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103286_bb0090","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1111\/jdv.18030","article-title":"Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0095","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2021.04.061","article-title":"Association between vaccination and autoimmune bullous diseases: a systematic review","volume":"86","author":"Kasperkiewicz","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjd.21240","article-title":"Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination","volume":"187","author":"Birabaharan","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0105","doi-asserted-by":"crossref","first-page":"807711","DOI":"10.3389\/fmed.2021.807711","article-title":"Case report: circulating anti-SARS-CoV-2 antibodies do not cross-react with pemphigus or pemphigoid autoantigens","volume":"8","author":"Kasperkiewicz","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2023.103286_bb0110","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1111\/jdv.18202","article-title":"Association between COVID-19 vaccination and autoimmune bullous diseases: a random coincidence or rare event","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0115","doi-asserted-by":"crossref","first-page":"957169","DOI":"10.3389\/fmed.2022.957169","article-title":"Exacerbation of autoimmune bullous diseases after severe acute respiratory syndrome coronavirus 2 vaccination: is there any association?","volume":"9","author":"Kianfar","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2023.103286_bb0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjd.20906","article-title":"COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the international pemphigus and pemphigoid foundation","volume":"186","author":"Kasperkiewicz","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2023.103286_bb0125","first-page":"e9","article-title":"Safety of the COVID-19 vaccine booster in patients with immunobullous diseases: a cross-sectional study of the international pemphigus and pemphigoid foundation","volume":"37","author":"Kasperkiewicz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0130","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/jdv.16525","article-title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"34","author":"Kasperkiewicz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0135","first-page":"e412","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0140","first-page":"e132","article-title":"A cross-sectional study of dermatologists' attitudes toward COVID-19 vaccination in patients with immunobullous diseases","volume":"37","author":"Kasperkiewicz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0145","first-page":"247","article-title":"Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios","volume":"157","author":"Cairoli","year":"2021","journal-title":"Med Clin (Engl Ed)"},{"key":"10.1016\/j.autrev.2023.103286_bb0150","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1111\/jdv.18180","article-title":"Role of the international pemphigus and pemphigoid foundation during the COVID-19 pandemic","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103286_bb0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(22)02075-X","article-title":"Monkeypox","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:30Z","timestamp":1761600450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1568997223000204"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103286","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 and autoimmune bullous diseases: Lessons learned","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103286"}}